옵션 체인은 다양한 행사가격과 만기일에 대한 Binah Capital Group의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Binah Capital Group에 대한 시장 심리를 평가합니다..

Binah Capital Group (NASDAQ:BCG) 주식, 옵션 체인

Binah Capital Group

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

Binah Capital Group Inc

BCGF Acquisition Corp

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:<a href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>), a leading AI infrastructure company, today announced that it has entered into definitive agreements for a private placement of senior unsecured convertible notes in an aggregate principal amount of $1 billion, in two tranches: $500,000,000 aggregate principal amount of 2.00% convertible notes due 2029 (the "2029 Notes"), and $500,000,000 aggregate principal amount of 3.00% convertible notes due 2031 (the "2031 Notes" and, together with the 2029 Notes, the "Notes").

News

Offerings

NBIS

Nebius Group Raises $1B Through Convertible Notes to Fuel AI Infrastructure Growth

Foreign policy and bond markets dominated the last week, as President Donald Trump&#8217;s postponement of 50% tariffs on the European Union lifted sentiment early. However, a weak Japanese long-dated bond auction on Wednesday signaled alarm.
The bid-to-cover ratio, a metric indicating the ratio between total bids and the total amount of securities offered for sale, was just 2.21 – far below the&nbsp;<a href="https://www.reuters.com/business/weak-demand-japans-40-year-debt-auction-shows-fiscal-stress-2025-05-28/">historical average of 3</a>. This structural imbalance between supply and demand for Japan&#8217;s debt might force the Bank of Japan to reconsider its plans for a future rate hike. In fact, it might go the other direction and intervene in the market to constrain spiking bond yields.
The currency pair of interest in this story will likely be CHF/JPY, as the Swiss National Bank has already eased rates (and even started discussing negative rates). However, the flag pattern has been setting up since early April and is now approaching its apex.
The week ahead is filled with news, including Powell&#8217;s speech on Monday, two key interest rate decisions (from the Bank of Canada and the European Central Bank), and the ever-important&nbsp;<a href="https://singaporeforexclub.com/what-is-the-nfp-in-forex">Non-Farm Payroll</a>&nbsp;report on the first Friday of the month.
<h2 class="wp-block-heading">Key News:</h2>
<ul class="wp-block-list">
<li>Monday: USD – ISM PMI, Powell Speech</li>
<li>Tuesday: CHF – CPI, JPY – Governor Ueda Speech, USD – JOLTS Jobs</li>
<li>Wednesday: AUD – GDP q/q, USD – ADP Change, ISM PMI, CAD – BOC Rate Decision</li>
<li>Thursday: EUR – Rate Decision, USD – Unemployment Claims</li>
<li>Friday: CAD – Unemployment, USD – Unemployment Rate, NFP</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">1.&nbsp; &nbsp; CHF JPY</h3>
This pair has been setting a bullish flag pattern since Yen&#8217;s decline in early April. A successful breakout would set the stage for a 430-pip move to take out the previous high from a year ago.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="433" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094653/CHFJPY_2025-06-01_19-07-45-1024x433.png" alt="" class="wp-image-13700" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094653/CHFJPY_2025-06-01_19-07-45-1024x433.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094653/CHFJPY_2025-06-01_19-07-45-300x127.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094653/CHFJPY_2025-06-01_19-07-45-768x324.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094653/CHFJPY_2025-06-01_19-07-45.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
CHF/JPY Daily Chart, Source: TradingView
<h3 class="wp-block-heading">2.&nbsp; &nbsp; EUR AUD</h3>
The euro has started rebounding against the Australian dollar, closing last week with a solid 130 pip advance. As long as the price stays clear of the buffer zone between 1.75640 and 1.75850, and doesn&#8217;t close the day below that zone, the likelihood of a strong upward move increases.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="440" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094637/EURAUD_2025-06-01_19-06-47-1024x440.png" alt="" class="wp-image-13699" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094637/EURAUD_2025-06-01_19-06-47-1024x440.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094637/EURAUD_2025-06-01_19-06-47-300x129.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094637/EURAUD_2025-06-01_19-06-47-768x330.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02094637/EURAUD_2025-06-01_19-06-47.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
EUR/AUD Daily Chart, Source: TradingView
Retail sentiment is 89% short, making this setup an excellent contrarian pick. The intermediate target is 1.78670.
Notes:
<ul class="wp-block-list">
<li>AUD NZD: Continues to weaken but might find stronger support around 1.07230.</li>
<li>AUD CAD: Started to descend lower, continuing the long-term bearish trend. Support is around 0.88.</li>
<li>AUD CHF: Broke out of the bearish flag, has yet to decline decisively, but it is biased to the downside.</li>
<li>AUD SGD: It remains in a range, with a slight bearish bias.</li>
<li>AUD JPY:  Indecisive, owing to weakness of both pairs. The long-term trend is downward.</li>
<li>CHF SGD: Still bullish bias, but failed to close above the key 1.57100 level. If it can bridge that gap, there is a potential for an upside move. However, traders pursuing multiple CHF trades should be aware of <a href="https://singaporeforexclub.com/correlated-forex-pairs">correlated forex pairs</a> and adjust risk management accordingly.</li>
<li>CAD JPY: Remains in a range, but it shows potential for reversing the trend and turning long-term bullish.</li>
<li>EUR JPY: Rebounded back to the 163.830 resistance level, still remains in the long-term consolidation.</li>
<li>EUR NZD: Remains range-bound without clear price action.</li>
<li>GBP AUD: Broke higher to find liquidity around 2.10280. It failed to break higher, showing significant signs of exhaustion. The important support is below at 2.08380.</li>
<li>GBP NZD: Showed signs of exhaustion, but until it breaks the strong support at 2.25120 and closes the day below that level, the bias remains to the upside.</li>
<li>NZD JPY: Failed to create a new higher high, but yet to create a lower low. It will likely remain in a range until some news catalyst moves the price.</li>
</ul>
Disclaimer: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. Singapore Forex Club is not responsible for any financial decisions based on this article's contents. We provide research and promote <a href="https://singaporeforexclub.com/how-to-start-trading-forex-in-singapore" target="_blank" rel="noreferrer noopener">forex trading in Singapore</a>, and readers may use this data for information and educational purposes only.

Forex

Global

Econ #s

Opinion

Trading Ideas

Bond Market Will Dictate BOJ's Next Move

LYRA: 319% &#x7C; <a href="https://www.benzinga.com//node/45717857">Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In A Composite Of The Three Cardinal Symptoms</a>
&nbsp;
CLF: 36% &#x7C; <a href="https://www.benzinga.com//node/45706950">President Donald Trump Says He Would Be Increasing Tariffs On Steel To 50% From 25%; Tariffs To Go Into Effect Next Week</a>
&nbsp;
&nbsp;

Movers

LYRA

Market-Moving News for June 2nd

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share ("EPS") or approximately $16.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2025 ("FY 2025"). This guidance is consistent with the guidance issued in the Company's press release dated April 30, 2025.
 &nbsp;

Guidance

Humana Reaffirms FY25 Guidance Of $14.68 EPS And $16.25 Adj EPS

Truist Securities analyst Matthew Coad initiates coverage on Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Buy rating and announces Price Target of $12.

Price Target

Initiation

Analyst Ratings

FLYW

Truist Securities Initiates Coverage On Flywire with Buy Rating, Announces Price Target of $12

KYMR

Kymera Therapeutics Shares Resume Trading, Up 55% After Reporting Data In The Phase 1 Healthy Volunteer Study Of KT-621

Truist Securities analyst Matthew Coad initiates coverage on SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Hold rating and announces Price Target of $14.

SOFI

Truist Securities Initiates Coverage On SoFi Technologies with Hold Rating, Announces Price Target of $14

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) on Monday disclosed a strategic collaboration with Shenzhen&#8217;s largest taxi operator, Shenzhen Xihu Corporation Limited, to deploy a fleet of over 1,000 Pony.ai&#8217;s seventh-generation Robotaxis in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45716395/pony-ai-inc-reaches-strategic-partnership-with-xihu-group-for-robotaxi-deployment-in-shenzhen" rel="noreferrer noopener">Shenzhen in the coming years</a>.
This partnership utilizes an &#8216;asset-light + AI-empowered model&#8217; to integrate autonomous driving with local mobility networks, with the goal of supporting the deployment of intelligent mobility services to more passengers in China&#8217;s tier-one cities, the company said.
Xihu Group will focus on fleet and asset operations, safety and service guarantees, and benefit economically from the fleet and asset operations.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45612556" rel="noreferrer noopener">Tesla Autonomous Driving Rival Pony AI To Expand Robotaxi Fleet Into Dubai Following Agreement With Regulators</a>
Meanwhile, Pony.ai will concentrate on AI technology innovations and scalable Robotaxi dispatch and services, fostering a mutually beneficial outcome that accelerates large-scale development.
This partnership merges Xihu Group&#8217;s operational know-how with Pony.ai&#8217;s proprietary hardware/software, AI-powered dispatch, and deep understanding of user needs to deliver a seamless autonomous mobility experience.
Pony has been on a collaboration spree to boost expansion across the world.
Last week, Pony AI announced that it signed a memorandum of understanding with Dubai&#8217;s Roads and Transport Authority to deploy <a target="_blank" href="https://www.benzinga.com/news/global/25/05/45628748/pony-ai-stock-is-up-today-whats-going-on" rel="noreferrer noopener">driverless taxis in the region</a>.
Notably, the company already has licenses in the U.S., South Korea, China and Luxembourg, and has more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45612556/tesla-autonomous-driving-rival-pony-ai-to-expand-robotaxi-fleet-into-dubai-following-agreement-with-regulators" rel="noreferrer noopener">270 robotaxis in its fleet</a> in China.
In May, the company confidentially filed for&nbsp;a Hong Kong initial public offering to help raise <a target="_blank" href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" rel="noreferrer noopener">capital to expand its business</a>.
Investors can gain exposure to the stock via First Trust S-Network Electric &amp; Future Vehicle Ecosystem ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARZ#NASDAQ">CARZ</a>).
Price Action: PONY shares are trading higher by 4.36% to $20.10 premarket at last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45514486/chinas-pony-ai-robotaxi-revenue-jumps-200-eyes-1000-vehicle-fleet" target="_blank" rel="noreferrer noopener">China&#8217;s Pony AI Robotaxi Revenue Jumps 200%, Eyes 1,000-Vehicle Fleet</a></li>
</ul>
Image via Shutterstock

Asia

Equities

Tech

CARZ

PONY

Pony.ai, Xihu Group To Deploy Over 1,000 Robotaxis In Shenzhen

Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.

FEMY

Femasys Prices 3.6M Share Public Offering At $0.85/Shr; Announces Private Placement Of 1.69M Shares At Up To $1.02/Shr

Truist Securities analyst Matthew Coad initiates coverage on Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy rating and announces Price Target of $181.

Truist Securities Initiates Coverage On Fiserv with Buy Rating, Announces Price Target of $181

Intellinetics, Inc. ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fir.intellinetics.com%2F&amp;,%20esheet=54262142&amp;,%20newsitemid=20250602527259&amp;,%20lan=en-US&amp;,%20anchor=NYSE+American%3A+INLX&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">INLX</a>), a digital transformation solutions provider, is pleased to announce that it has been awarded a five-year contract with a long-term customer for document scanning and micrographic conversions services worth up to an estimated aggregate $40 million in Total Contract Value (TCV). The revenue will be recognized as work is completed on projects spanning the contract period, which runs from June 1, 2025 through May 31, 2030 plus an optional five more extension years.
The contract, the largest in the company's history, was awarded following a competitive evaluation process. Specific standards and procedures for quality assurance, security, key personnel, and depth and breadth of service were assessed and scored to determine the vendor of choice. The $40 million TCV is based upon the customer's procurement budget, but subject to customer reduction or termination in its sole discretion during the contract period.

INLX

Intellinetics Lands $40M Deal, Largest in Company History, for Document Scanning Services

Apple&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) former designer and a key mind behind the first iPhone, Jony Ive says the hardest part of creativity isn't dreaming up lofty ideas, it&#8217;s having the nerve to drop most of them — a lesson he learnt from Steve Jobs.
What Happened: In a 2014 on-stage conversation with Vanity Fair editor Graydon Carter, Apple's then–design chief recalled the single lesson Steve Jobs drilled into him: relentless focus. "This sounds really simplistic, but it still shocks me how few people actually practice this," Ive told the New Establishment Summit crowd.
Jobs, whom Jony Ive called "the most remarkably focused person I've ever met," kept score with a blunt question: "How many things have you said no to?" Ive confessed he sometimes produced "sacrificial" examples — projects he never liked anyway, only to be caught. True focus, he explained, means saying no &#8220;to something that, with every bone in your body, you think is a phenomenal idea,&#8221; because it distracts from the mission at hand.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Jony Ive on what Steve Jobs taught him about focus" width="500" height="281" src="https://www.youtube.com/embed/EKBVLzOZyLw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The clip has resurfaced online as a pocket-sized master class in priority-setting, racking up millions of impressions on X and LinkedIn posts that repeat Ive's warning that focus is an "every-minute" discipline, not a Monday-morning resolution.
See also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45716400/pharma-bro-martin-shkreli-sees-10-trillion-potential-in-palantir-but-cautions-one-bad-quarter-and-its-down-50">&#8216;Pharma Bro&#8217; Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: &#8216;One Bad Quarter And It&#8217;s Down 50%&#8217;</a>
The mantra helps explain why Apple routinely axed promising prototypes, an approach former Wall Street Journal editor Walter Isaacson says let Jobs spend &#8220;<a href="https://www.benzinga.com/general/24/04/38403093/steve-jobs-spent-hour-after-hour-on-product-design-he-cared-about-god-being-in-the-details-says-walt">hour after hour</a>&#8221; on seemingly the smallest bits of product design that made products iconic.
Why It Matters: Other CEOs have since borrowed the mantra. Salesforce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) Marc Benioff credits a <a href="https://www.benzinga.com/25/05/45559653/steve-jobs-once-invited-marc-benioff-to-his-office-with-two-ipads-in-2010-the-lesson-that-shaped-a-270-billion-salesforce-empire">2010 chat with Jobs</a> for sharpening his own product discipline. Disney's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) Bob Iger received a different kind of counsel as Jobs urged him to <a href="https://www.benzinga.com/news/24/09/40787212/steve-jobs-urged-bob-iger-to-retire-and-enjoy-life-before-its-too-late-heres-how-that-advice-shaped">retire and enjoy life</a> before it's too late, advice the executive says still frames how he paces his tenure at the entertainment giant.
Apple&#8217;s chief Tim Cook recalls that <a href="https://www.benzinga.com/24/11/42090539/tim-cook-goes-from-small-town-to-ceo-of-worlds-largest-company-why-he-believes-in-asking-lots-of-questions">Jobs&#8217; parting words</a>, shared the night before his death, were simply to do what he thought was right when it came to leading Apple.
Snowflake&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) Frank Slootman had his own key takeaway from Jobs&#8217; management philosophies. Slootman believes the late Jobs always either found a product &#8220;insanely great&#8221; or &#8220;sh&#x2A;t&#8221; and that approach ensured there was never any <a href="https://www.benzinga.com/news/management/25/05/45604617/steve-jobs-wasnt-happy-unless-things-were-insanely-great-and-thats-why-this-tech-ceo-is-passionate-about-moving-mental-boundaries-that-withhold-pe">room for mediocrity</a> within the company&#8217;s walls.
Read next: <a href="https://www.benzinga.com/news/politics/25/06/45716936/speaker-mike-johnson-says-4-8-million-wont-lose-medicaid-unless-they-choose-to-do-so-calls-gop-cuts-an-important-and-frankly-heroic-thing">Speaker Mike Johnson Says 4.8 Million Won&#8217;t Lose Medicaid &#8216;Unless They Choose To Do So,&#8217; Calls GOP Cuts &#8216;An Important And Frankly Heroic Thing&#8217;</a>

General

AAPL

SNOW

Jony Ive Once Said Steve Jobs Demanded Everyone At Apple Often Answer This Question: 'It Still Shocks Me How Few People Actually Practice This'

South African Firm Commits to Driving American Industrial Renewal and Africa-U.S. Commercial Diplomacy
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 2, 2025 / American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources"), through its holding in ReElement Technologies Corporation ("ReElement"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, announced today that Novare Holdings Proprietary Limited ("Novare"), a South African-headquartered institutional investment firm, has committed to be the anchor investor in ReElement's private capital raise. This commitment will help unlock approximately $150 million in combined equity and debt financing to expand ReElement's refining operations at its 42-acre Marion, Indiana supersite - revitalizing the former RCA-Thomson television factory, once a symbol of American industrial strength. ReElement is proud to revive the facility as a hub for advanced manufacturing, signaling the return of high-value industry to the American heartland.

AREC

American Resources Secures $150M Investment To Expand Rare Earth Refining

BriaCell Therapeutics Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ)), (TSX:<a href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=790IRU9LzZ0Dxe4XexrZDEDviwlJpdgB-1C1QC9E2Vb8F-p7I7cPdraEg974je-7iVaUfa4gjc8h1nNbivVKFaYoKoMKOAHQnKcsQijafmsokbVa43Zf8L9JQ3y0zyD8">NCT06072612</a>), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=790IRU9LzZ0Dxe4XexrZDFfXNgbntwwBxg8-h8afaozqcUDEFcFxDyPAp_kKbs497Y7f3nFjOcvH7xEwpgK4Eg0mKY4_KJNHUSEa_5_qs1dW9vFRlmT2j4CdMeIXa0ahIr1-ffU-qalVCBxlUROrV88iHMsE1u7bAa90JoGSQydQiOtszLGcKkyrdp5oLBD3TOJOYWtuBZsbc2kX5Kir18CSFB1HLaXVA2orOo-ZHysYqaFYvUicAICItxvNRk4tkYMsuhcqUiGda_NeF5xiQbPb02L6lOVcygJpsyNuaM2fTKK1aaBcPbu0L--LgH72">NCT06471673</a>) in metastatic breast cancer.

BCTX

BriaCell Highlights Breast Cancer Trial Data at 2025 ASCO Annual Meeting

Biotech

Health Care

CNTX

Context Therapeutics Is Presenting A Trial In Progress Poster For The Phase 1 Trial Of CTIM-76 In Ovarian, Endometrial, And Testicular Cancers At The 2025 American Society Of Clinical Oncology Annual Meeting, Expect To Share Initial Data In The First Half Of 2026

Truist Securities analyst Matthew Coad initiates coverage on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Hold rating and announces Price Target of $97.

FOUR

Truist Securities Initiates Coverage On Shift4 Payments with Hold Rating, Announces Price Target of $97

Truist Securities analyst Matthew Coad initiates coverage on Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) with a Hold rating and announces Price Target of $11.

LSPD

Truist Securities Initiates Coverage On Lightspeed Commerce with Hold Rating, Announces Price Target of $11

<ul>
<li>Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.</li>
<li>INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.</li>
<li>Median PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two years &nbsp;</li>
</ul>

INAB

IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival

<ul>
<li>ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue</li>
<li>Study initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM&#x2122;) platform</li>
<li>In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.

ARWR

Arrowhead Pharma Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-ALK7, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Obesity

Shares of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose sharply in <a href="https://www.benzinga.com/quote/BPMC/news">today's pre-market trading</a>.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines for $9.5 billion.
Blueprint Medicines shares jumped 26.9% to $128.62 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares jumped 199% to $14.74 in pre-market trading after the company reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of Chronic Rhinosinusitis (CRS).</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) rose 93.2% to $4.81 in pre-market trading.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) surged 69% to $32.02 in pre-market trading after the company said Atacicept ORIGIN Phase 3 trial met primary endpoint of reduction in UPCR for IgAN treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) jumped 68.5% to $0.47 in pre-market trading after gaining 13% on Friday.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) surged 51.4% to $9.20 in pre-market trading after jumping 485% on Friday.</li>
<li>Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) gained 37.3% to $13.29 in pre-market trading after falling 5% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) climbed 27.7% to $1.6990 in pre-market trading after jumping 24% on Friday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rose 25.6% to $7.32 in pre-market trading.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 14.1% to $109.32 in pre-market trading. BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 23.2% to $3.77 in pre-market trading. ReShape Lifesciences entered into equity distribution agreement relating to sale of up to $9.7 million of shares of common stock.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 22.6% to $0.7500 in pre-market trading after the company announced suspension of Nasdaq trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 20.2% to $0.8300 in pre-market trading after gaining 8% on Friday.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) fell 17.9% to $0.8788 in pre-market trading after the company announced a proposed public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 16.4% to $0.1629 in today's pre-market trading. Super League Enterprise, on Friday, announced a registered direct offering.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 16% to $1.68 in pre-market trading. TIAN RUIXIANG shares gained 8% on Friday after the company announced plans to buy Ucare for $150 million in an all-stock deal.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 MILLION.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ASTL

BMGL

BNAI

BNTX

BPMC

BSII

CLEU

FAAS

LOGC

LUCD

RSLS

SBET

SLXN

TIRX

VERA

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

Press Releases

PKS Investments, a Subsidiary of Binah Capital Group, Recognized as One of Albany's Best Places to Work

Management

Binah Capital Group Chief Executive Officer Recognized by the Prestigious InvestmentNews Hot List

Binah Capital Recognized Among Industry Leaders in the Financial Planning's Top Deal Makers List "Top IBD Moves and M&A Deals of 2024"

Earnings

Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results

Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report

Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer

Bleakley Financial Group Chooses PKS Investments, a Subsidiary of Binah Capital Group, as Broker-Dealer for Hybrid Advisory Services

Comments

Binah Capital Group

Binah Capital Group (BCG) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌